PCBL Chemical Ltd

- The company has reduced overall borrowings by approximately INR 450 crores in the current year. - Working capital management has improved, with tighter controls on receivables and inventory. - Despite higher crude prices, the company expects to require only around INR 100 crores of incremental working capital. - Cash generation from higher volumes and better margins is expected to comfortably cover growth investments, shareholder payouts, and incremental working capital needs. - There is no explicit mention of new fundraising through debt or equity in the provided transcript. - The management emphasizes maintaining capital discipline and generating cash internally to fund growth and reduce leverage.

- PCBL Chemical Limited is in the process of expanding capacity for green chelates in Aquapharm, awaiting product approvals from P&G, Henkel, and others before setting up additional capacity. - The company plans significant capacity additions for Aquapharm's green chelates portfolio in FY27 and FY28 as sales increase. - A pilot plant for the battery chemicals business (Nanovace) at Palej is ready for commissioning soon, with commercial volumes expected to start in FY28 after validation. - A project on coal-tar-based feedstock diversification is underway, with feasibility being finalized and capex investment sign-off expected in upcoming calls. - Cost reduction initiatives targeting INR 200-250 crores savings over 4-6 quarters are ongoing, including yield improvement, throughput enhancement, and feedstock diversification. - PCBL aims to continue investing in growth capex while reducing overall debt, with net leverage expected to decline.

- Carbon black volume growth expected at high single digits (7-10%) for FY27 with more than double-digit EBITDA growth. - Green chelates (Aquapharm) revenue expected to grow significantly, with 20-25% top-line growth forecast for FY27. - Expansion plans underway for green chelates capacity post product approvals from P&G and Henkel; trial orders received and supplies started. - Tyre business volumes expected to increase from Q1 FY27 onwards, recovering from slight QoQ decline. - Aquapharm EBITDA projected to improve strongly, targeting INR75 crores quarterly run rate, and potentially INR50-55 crores EBITDA per quarter next year. - Market expansions through India-EU FTA and increased exports to the US post tariff reduction expected to drive volume and revenue growth. - Battery chemical segment (Nanovace) to begin commercial volume ramp-up from FY28 after pilot plant commissioning and product validations. - Overall revenue growth driven by volume increases, improved product mix, pricing, and cost efficiency initiatives.

- PCBL Chemical Limited expects **double-digit growth in EBITDA per ton for FY27**, with a 14-15% increase anticipated due to pricing, product mix improvements, and cost initiatives. - **Volume growth** for carbon black is expected to be **high single digits (7-10%)** next year, driving overall revenue and profitability growth. - The Aquapharm segment is projected to see **20-25% top-line growth in FY27**, with EBITDA expected to increase significantly, potentially returning to INR50-55 crores per quarter. - The company anticipates **higher tyre business volumes from Q1 FY27 onwards**. - Profitability is expected to **surpass FY25 base case EBITDA and PAT** levels. - Long-term guidance remains robust, with a target of INR40 billion EBITDA by 2030 still on track despite current short-term challenges. - Battery chemicals business pilot is ready; **commercial volumes expected from FY28**, contributing future profits.

- PCBL Chemical has started receiving trial orders from key customers like P&G and Henkel for their green chelates portfolio (Aquapharm segment). - Supplies for these trial orders have commenced, with significant volume and revenue ramp-up expected from Q2 and Q3 FY27 onwards as product approvals come through. - The potential market opportunity for these customers is large, exceeding their current capacity of 4,000 tons, indicating plans for capacity expansion once approvals are received. - The company is also working with additional customers for product approvals in the non-detergent segment to broaden the order book. - Overall, the order pipeline is strong, with Aquapharm expected to see 20-25% revenue growth in FY27 fueled by these new and incremental allocations.